

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	10/623,908
		Filing Date	July 21, 2003
		First Named Inventor	Paul J. Kawula
		Group Art Unit	3731
		Examiner Name	Unassigned
Total Number of Pages in This Submission (excluding references)	13	Attorney Docket Number	50623.245

ENCLOSURES (check all that apply)

<input checked="" type="checkbox"/> Deposit Account Authorization 07-1850	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input checked="" type="checkbox"/> Postage Paid Return Postcard	<input type="checkbox"/> Formal Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Response to Office Action <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Submission of Formal Drawings (in duplicate)
<input type="checkbox"/> Petition for Extension of Time (month) (in duplicate)	<input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Amendment Transmittal Letter (in duplicate)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input checked="" type="checkbox"/> Information Disclosure Statement with Form PTO-1449 and <u>84</u> References	Remarks	
<input type="checkbox"/> Request for Continued Examination (RCE) Transmittal		
<input type="checkbox"/> Express Mail Label No.		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Squire, Sanders & Dempsey L.L.P. Charles B. Runyan, Reg. No. 43,066
-------------------------	--

Signature

Date

March 3, 2004

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date:

Typed or printed name	Dilore Haddad
Signature	
Date	March <u>3</u> , 2004

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



~~IN THE UNITED STATES PATENT AND TRADEMARK OFFICE~~

In re Application of: Examiner: Unassigned

Paul J. Kawula

Serial No. 10/623,908 Art Unit: 3731

Filed: July 21, 2003

Title: Porous Glass Fused Onto Stent for Drug Retention

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §§1.97-1.98**

Dear Examiner:

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and pursuant to 37 C.F.R. §§1.97-1.98, Applicant hereby notifies the U.S. Patent and Trademark Office of the references listed on the attached Form PTO-1449. According to a Notice signed July 11, 2003, the U.S. Patent and Trademark Office has waived the requirement under 37 C.F.R. § 1.98(a)(2)(i) for all patent applications filed after June 30, 2003. *See*, 1276 Off. Gaz. Pat. Office 55. Since this patent application was filed after June 30, 2003, Applicant has not provided copies of the cited U.S. patents or the U.S. Patent Application Publications. Copies of the cited foreign patent documents and non-patent literature have been submitted herewith.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant reserves the right to dispute the listed documents as prior art during examination. Furthermore, Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application. The submission of this Information Disclosure Statement is not to be construed as a representation that a search has been made or that no other material information may exist.


The Examiner is requested to initial the enclosed Form PTO-1449 and return a copy thereof to the undersigned.

The present Information Disclosure Statement is being filed before receiving the first Office Action. Therefore, no certification under 37 C.F.R. §1.97(e) or fee under 37 C.F.R. §1.17(p) is required. However, the Commissioner is authorized to charge any deficiencies or other amounts due to Deposit Account No. 07-1850.

Date: March 3, 2004

SQUIRE, SANDERS & DEMPSEY L.L.P.
One Maritime Plaza, Suite 300
San Francisco, CA 94111
Telephone (415) 954-0200
Facsimile (415) 393-9887

Respectfully submitted,



Charles E. Runyan
Attorney for Applicant
Reg. No. 43,066

FORM PTO-1449 (Modified)		U.S. DEPARTMENT OF COMMERCE US Patent and Trademark Office		Docket No. 50623.245	Application No. 10/623,908
Approved for use through 10/31/2002				Applicant Paul J. Kawula	
INFORMATION DISCLOSURE CITATION in an Application (Use several sheets if necessary)				Filing Date July 21, 2003	Group Art Unit 3731

U.S. PATENT DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate
	A1	4,329,383	5/11/82	Joh	428	36	7/21/80
	A2	4,459,252	07/10/84	MacGregor	264	46.9	
	A3	4,733,665	3/29/88	Palmaz	128	343	11/7/85
	A4	4,800,882	1/31/89	Gianturco	128	343	3/13/87
	A5	4,882,168	11/21/89	Casey et al.	424	468	9/5/86
	A6	4,886,062	12/12/89	Wiktor	128	343	10/19/87
	A7	4,941,870	7/17/90	Okada et al.	600	36	12/30/88
	A8	4,977,901	12/18/90	Ofstead	128	772	4/6/90
	A9	5,059,211	10/22/91	Stack et al.	606	198	
	A10	5,112,457	5/12/92	Marchant	204	165	7/23/90
	A11	5,163,952	11/17/92	Froix	623	1	
	A12	5,165,919	11/24/92	Sasaki et al.	424	488	9/26/90
	A13	5,272,012	12/21/93	Opolski	428	423.1	1/29/92
	A14	5,292,516	3/8/94	Viegas et al.	424	423	11/8/91
	A15	5,298,260	3/29/94	Viegas et al.	424	486	6/9/92
	A16	5,300,295	4/5/94	Viegas et al.	424	427	9/13/91
	A17	5,306,501	4/26/94	Viegas et al.	424	423	11/8/91
	A18	5,306,286	04/26/94	Stack et al.	606	198	
	A19	5,328,471	7/12/94	Slepian	604	101	8/4/93
	A20	5,330,768	7/19/94	Park et al.	424	501	7/5/91
	A21	5,380,299	1/10/95	Fearnott et al.	604	265	8/30/93
	A22	5,417,981	5/23/95	Endo et al.	424	486	4/28/93
	A23	5,447,724	9/5/95	Helmus et al.	424	426	11/15/93
	A24	5,455,040	10/3/95	Marchant	424	426	11/19/92
	A25	5,462,990	10/31/95	Hubbell et al.	525	54.1	10/5/93
	A26	5,464,650	11/7/95	Berg et al.	427	2.30	4/26/93

A27	5,527,337	06/18/96	Stack et al.	606	198	
A28	5,569,463	10/29/96	Helmus et al.	424	426	6/7/95
A29	5,578,073	11/26/96	Haimovich et al.	623	1	9/16/94
A30	5,605,696	2/25/97	Eury et al.	424	423	3/30/95
A31	5,609,629	3/11/97	Fearnott et al.	623	1	6/7/95
A32	5,624,411	4/29/97	Tuch	604	265	6/7/95
A33	5,628,730	5/13/97	Shapland et al.	604	21	7/18/94
A34	5,649,977	7/22/97	Campbell	623	1	9/22/94
A35	5,658,995	8/19/97	Kohn et al.	525	432	11/27/95
A36	5,667,767	9/16/97	Greff et al.	424	9.411	7/27/95
A37	5,670,558	9/23/97	Onishi et al.	523	112	7/6/95
A38	5,679,400	10/21/97	Tuch	427	2.14	6/7/95
A39	5,700,286	12/23/97	Tartaglia et al.	623	1	
A40	5,700,286	12/23/97	Tartaglia et al.	623	1	8/22/96
A41	5,702,754	12/30/97	Zhong	427	2.12	2/22/95
A42	5,713,949	02/03/98	Jayaraman	623	1	
A43	5,716,981	2/10/98	Hunter et al.	514	449	6/7/95
A44	5,735,897	4/7/98	Buirge	623	12	1/2/97
A45	5,746,998	5/5/98	Torchilin et al.	424	9.4	8/8/96
A46	5,766,710	06/16/98	Turnlund et al.	428	36.1	
A47	5,769,883	06/23/98	Buscemi et al.	623	1	
A48	5,776,184	7/7/98	Tuch	623	1	10/9/96
A49	5,788,979	8/4/98	Alt et al.	424	426	2/10/97
A50	5,800,392	9/1/98	Racchini	604	96	5/8/96
A51	5,820,917	10/13/98	Tuch	427	2.1	6/7/95
A52	5,824,048	10/20/98	Tuch	623	1	10/9/96
A53	5,824,049	10/20/98	Ragheb et al.	623	1	10/31/96
A54	5,830,178	11/3/98	Jones et al.	604	49	10/11/96
A55	5,837,008	11/17/98	Berg et al.	623	1	4/27/95
A56	5,837,313	11/17/98	Ding et al.	427	2.21	6/13/96
A57	5,843,172	12/01/98	Yan	623	1	
A58	5,851,508	12/22/98	Greff et al.	424	9.411	2/14/97

A59	5,858,746	1/12/99	Hubbell et al.	435	177	1/25/95
A60	5,865,814	2/2/99	Tuch	604	265	8/6/97
A61	5,869,127	2/9/99	Zhong	427	2.12	6/18/97
A62	5,873,904	02/23/99	Ragheb	623	1	
A63	5,873,904	2/23/99	Ragheb et al.	623	1	2/24/97
A64	5,876,433	3/2/99	Lunn	623	1	5/29/96
A65	5,877,224	3/2/99	Broccini et al.	514	772.2	7/28/95
A66	5,925,720	7/20/99	Kataoka et al.	525	523	12/18/97
A67	5,955,509	9/21/99	Webber et al.	514	772.7	4/23/97
A68	5,971,954	10/26/99	Conway et al.	604	96	1/29/97
A69	5,980,928	11/9/99	Terry	424	427	7/29/97
A70	5,980,972	11/9/99	Ding	427	2.24	9/22/97
A71	5,997,517	12/7/99	Whitbourne	604	265	1/27/97
A72	6,010,530	1/4/00	Goicoechea	623	1	2/18/98
A73	6,015,541	1/18/00	Greff et al.	424	1.25	11/3/97
A74	6,033,582	3/7/00	Lee et al.	216	37	1/16/98
A75	6,042,875	3/28/00	Ding et al.	427	2.24	3/2/99
A76	6,051,648	4/18/00	Rhee et al.	525	54.1	1/13/99
A77	6,051,576	4/18/00	Ashton et al.	514	255	1/29/97
A78	6,056,993	5/2/00	Leidner et al.	427	2.25	4/17/98
A79	6,060,451	5/9/00	DiMaio et al.	514	13	3/20/95
A80	6,060,518	5/9/00	Kabanov et al.	514	781	8/16/96
A81	6,080,488	6/27/00	Hostettler et al.	428	423.3	3/24/98
A82	6,096,070	8/1/00	Ragheb et al.	623	1	5/16/96
A83	6,099,562	8/8/00	Ding et al.	623	1.46	12/22/97
A84	6,110,188	8/29/00	Narciso, Jr.	606	153	3/9/98
A85	6,110,483	8/29/00	Whitbourne et al.	424	423	6/23/97
A86	6,113,629	9/5/00	Ken	623	1.1	5/1/98
A87	6,120,536	9/19/00	Ding et al.	623	1.43	
A88	6,120,847	9/19/00	Yang et al.	427	335	
A89	6,120,536	9/19/00	Ding et al.	623	1.43	6/13/96
A90	6,120,904	9/19/00	Hostettler et al.	428	423.3	5/24/99
A91	6,121,027	9/19/00	Clapper et al.	435	180	8/15/97

A92	6,129,761	10/10/00	Hubbell	623	11	6/7/95
A93	6,153,252	11/28/00	Hossainy et al.	427	2.3	4/19/99
A94	6,165,212	12/26/00	Dereume et al.	623	1.13	6/28/99
A95	6,203,551	3/20/01	Wu	606	108	10/4/99
A96	6,206,915	3/27/01	Fagan et al.	623	1.42	
A97	6,231,600	5/15/01	Zhong	623	1.42	5/26/99
A98	6,240,616	6/5/01	Yan	29	527.2	4/15/97
A99	6,245,753	6/12/01	Byun et al.	514	56	4/27/99
A100	6,251,136	6/26/01	Guruwaiya et al.	623	1.46	12/8/99
A101	6,254,632	7/3/01	Wu et al.	623	1.15	9/28/00
A102	6,258,121	7/10/01	Yang et al.	623	1.46	7/2/99
A103	6,283,947	9/4/01	Mirzaee	604	264	7/13/99
A104	6,283,949	9/4/01	Roorda	604	288.02	12/27/99
A105	6,284,305	9/4/01	Ding et al.	427	2.28	5/18/00
A106	6,287,628	9/11/01	Hossainy et al.	427	2.3	9/3/99
A107	6,299,604	10/9/01	Ragheb et al.	604	265	8/20/99
A108	6,306,176	10/23/01	Whitbourne	623	23.59	9/21/99
A109	6,331,313	12/18/01	Wong et al.	424	427	10/22/99
A110	6,335,029	1/1/02	Kamath et al.	424	423	12/3/98
A111	6,346,110	2/12/02	Wu	606	108	1/3/01
A112	6,358,556	3/19/02	Ding et al.	427	2.24	1/23/98
A113	6,379,381	4/30/02	Hossainy et al.	623	1.42	9/3/99
A114	6,395,326	5/28/02	Castro et al.	427	2.24	5/31/00
A115	6,419,692	7/16/02	Yang et al.	623	1.15	2/3/99
A116	6,451,373	9/17/02	Hossainy et al.	427	2.25	8/4/00
A117	6,494,862	12/17/02	Ray et al.	604	96.01	12/30/99
A118	6,503,556	1/7/03	Harish et al.	427	2.24	12/28/00
A119	6,503,954	1/7/03	Bhat et al.	514	772.2	7/21/00
A120	6,506,437	1/14/03	Harish et al.	427	2.25	10/17/00

	A121	6,527,801	3/4/03	Dutta	623	1.46	4/13/00
	A122	6,527,863	3/4/03	Pacetti et al.	118	500	6/29/01
	A123	6,540,776	4/1/03	Sanders Millare et al.	623	1.15	12/28/00
	A124	6,544,223	4/8/03	Kokish	604	103.01	1/5/01
	A125	6,544,543	4/8/03	Mandrusov et al.	424	422	12/27/00
	A126	6,544,582	4/8/03	Yoe	427	2.24	1/5/01
	A127	6,555,157	4/29/03	Hossainy	427	2.24	7/25/00
	A128	6,558,733	5/6/03	Hossainy et al.	427	2.24	10/26/00
	A129	6,565,659	5/20/03	Pacetti et al.	118	500	6/28/01
	A130	6,572,644	6/3/03	Moein	623	1.11	6/27/01
	A131	6,585,765	7/1/03	Hossainy et al.	623	1.45	6/29/00
	A132	6,585,926	7/1/03	Mirzaee	264	400	8/31/00
	A133	6,605,154	8/12/03	Villareal	118	500	5/31/01

U.S. PATENT APPLICATION PUBLICATION DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Publication	Name	Class	Subclass	Filing Date if Appropriate
	A134	2001/0018469	8/30/01	Chen et al.	523	121	12/28/00
	A135	2001/0037145	11/1/01	Guruwaiya et al.	623	1.15	6/21/01
	A136	2002/0077693	6/20/02	Barclay et al.	623	1.13	12/19/00
	A137	2002/0091433	7/11/02	Ding et al.	623	1.2	12/17/01
	A138	2002/0155212	10/24/02	Hossainy	427	2.25	4/24/01
	A139	2003/0065377	4/3/03	Davila et al.	623	1.13	4/30/02
	A140	2003/0099712	5/29/03	Jayaraman	424	486	11/26/01

FOREIGN PATENT DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Translation	
							Yes	No
	B1	EP 0 301 856	2/1/89	European				
	B2	WO 90/01969	03/08/90	PCT				
	B3	WO 91/12846	9/5/91	PCT				
	B4	EP 0 514 406	11/25/92	European				
	B5	EP 0 604 022	6/29/94	European				
	B6	EP 0 623 354	11/9/94	European				
	B7	WO 95/10989	4/27/95	PCT				

B8	EP 0 665 023	8/2/95	European			
B9	EP 0 701 802	3/20/96	European			
B10	EP 0 716 836	6/19/96	European			
B11	WO 96/40174 ?	12/19/96	PCT			
B12	WO 97/10011	3/20/97	PCT			
B13	EP 0 809 999	12/3/97	European			
B14	WO 97/45105 ?	12/4/97	PCT			
B15	WO 97/46590	12/11/97	PCT			
B16	EP 0850651 (A2 & A3)	01/07/98	Europe	A61L	27/00	
B17	EP 0 832 655	4/1/98	European			
B18	EP 0875218 (A2 & A3)	04/11/98	Europe	A61F	2/06	
B19	WO 98/17331	4/30/98	PCT			
B20	WO 98/23228	06/04/98	PCT			
B21	EP 0 850 651	7/1/98	European			
B22	WO 98/36784	8/27/98	PCT			
B23	EP 0 879 595	11/25/98	European			
B24	WO 99/01118 ?	1/14/99	PCT			
B25	JP/11299901	02/11/99	Japan	A61M	29/02	
B26	WO 99/16386	04/08/99	PCT	A61F	2/06	
B27	EP 0 910 584	4/28/99	European			
B28	EP 0 923 953	6/23/99	European			
B29	WO 99/38546	8/5/99	PCT			
B30	EP 0 953 320	11/3/99	European			
B31	WO 99/63981	12/16/99	PCT			
B32	EP 0 970 711	1/12/00	European			
B33	WO 00/02599	1/20/00	PCT			
B34	EP 0 982 041	3/1/00	European			
B35	WO 00/12147	3/9/00	PCT			
B36	WO 00/18446	4/6/00	PCT			
B37	WO 00/64506	11/2/00	PCT			
B38	WO 01/01890	1/11/01	PCT			

B39	WO 01/15751	3/8/01	PCT				
B40	WO 01/17577	3/15/01	PCT				
B41	WO 01/45763	6/28/01	PCT				
B42	WO 01/49338	7/12/01	PCT				
B43	2001-190687	7/17/01	Japan (Abstract)				X
B44	WO 01/74414	10/11/01	PCT				
B45	WO 02/03890	1/17/02	PCT				
B46	WO 02/026162	4/4/02	PCT				
B47	WO 02/34311	5/2/02	PCT				
B48	WO 02/056790	7/25/02	PCT				
B49	WO 03/000308	1/3/03	PCT				
B50	EP 1 273 314	1/8/03	European				
B51	WO 03/022323	3/20/03	PCT				
B52	WO 03/028780	4/10/03	PCT				
B53	WO 03/037223	5/8/03	PCT				
B54	WO 03/039612	5/15/03	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C1	Anonymous, <i>Cardiologists Draw - Up The Dream Stent</i> , Clinica 710:15 (June 17, 1996), http://www.dialogweb.com/cgi/document?req=1061848202959 , printed 8/25/03 (2 pages).
C2	Anonymous, <i>Heparin-coated stents cut complications by 30%</i> , Clinica 732:17 (Nov. 18, 1996), http://www.dialogweb.com/cgi/document?req=1061847871753 , printed 8/25/03 (2 pages).
C3	Anonymous, <i>Rolling Therapeutic Agent Loading Device for Therapeutic Agent Delivery or Coated Stent (Abstract 434009)</i> , Res. Disclos. pp. 974-975 (June 2000).
C4	Anonymous, <i>Stenting continues to dominate cardiology</i> , Clinica 720:22 (Sept. 2, 1996), http://www.dialogweb.com/cgi/document?req=1061848017752 , printed 8/25/03 (2 pages).
C5	Aoyagi et al., <i>Preparation of cross-linked aliphatic polyester and application to thermo-responsive material</i> , Journal of Controlled Release 32:87-96 (1994).
C6	Barath et al., <i>Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury</i> , JACC 13(2): 252A (Abstract) (Feb. 1989).
C7	Barbucci et al., <i>Coating of commercially available materials with a new heparinizable material</i> , J. Biomed. Mater. Res. 25:1259-1274 (Oct. 1991).
C8	Chung et al., <i>Inner core segment design for drug delivery control of thermo-responsive polymeric micelles</i> , Journal of Controlled Release 65:93-103 (2000).
C9	Dev et al., <i>Kinetics of Drug Delivery to the Arterial Wall Via Polyurethane-Coated Removable Nitinol Stent: Comparative Study of Two Drugs</i> , Catheterization and Cardiovascular Diagnosis 34:272-278 (1995).
C10	Dichek et al., <i>Seeding of Intravascular Stents with Genetically Engineered Endothelial Cells</i> , Circ. 80(5):1347-1353 (Nov. 1989).
C11	Eigler et al., <i>Local Arterial Wall Drug Delivery from a Polymer Coated Removable Metallic Stent: Kinetics, Distribution, and Bioactivity of Forskolin</i> , JACC, 4A (701-1), Abstract (Feb. 1994).
C12	Helmus, <i>Overview of Biomedical Materials</i> , MRS Bulletin, pp. 33-38 (Sept. 1991).

	C13	Herdeg et al., <i>Antiproliferative Stent Coatings: Taxol and Related Compounds</i> , Semin. Intervent. Cardiol. 3:197-199 (1998).
	C14	Inoue et al., <i>An AB block copolymer of oligo(methyl methacrylate) and poly(acrylic acid) for micellar delivery of hydrophobic drugs</i> , Journal of Controlled Release 51:221-229 (1998).
	C15	Kataoka et al., <i>Block copolymer micelles as vehicles for drug delivery</i> , Journal of Controlled Release 24:119-132 (1993).
	C16	Levy et al., <i>Strategies For Treating Arterial Restenosis Using Polymeric Controlled Release Implants</i> , Biotechnol. Bioact. Polym. [Proc. Am. Chem. Soc. Symp.], pp. 259-268 (1994).
	C17	Liu et al., <i>Drug release characteristics of unimolecular polymeric micelles</i> , Journal of Controlled Release 68:167-174 (2000).
	C18	Marconi et al., <i>Covalent bonding of heparin to a vinyl copolymer for biomedical applications</i> , Biomaterials 18(12):885-890 (1997).
	C19	Matsumaru et al., <i>Embolic Materials For Endovascular Treatment of Cerebral Lesions</i> , J. Biomater. Sci. Polymer Edn 8(7):555-569 (1997).
	C20	Miyazaki et al., <i>Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice</i> , Chem. Pharm. Bull. 33(6) 2490-2498 (1985).
	C21	Miyazawa et al., <i>Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat</i> , J. Cardiovasc. Pharmacol., pp. 157-162 (1997).
	C22	Nordrehaug et al., <i>A novel biocompatible coating applied to coronary stents</i> , European Heart Journal 14, p. 321 (P1694), Abstr. Suppl. (1993).
	C23	Ohsawa et al., <i>Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty</i> , American Heart Journal 136(6):1081-1087 (Dec. 1998).
	C24	Ozaki et al., <i>New Stent Technologies</i> , Progress in Cardiovascular Diseases, Vol. XXXIX(2):129-140 (Sept./Oct. 1996).
	C25	Pechar et al., <i>Poly(ethylene glycol) Multiblock Copolymer as a Carrier of Anti-Cancer Drug Doxorubicin</i> , Bioconjugate Chemistry 11(2):131-139 (Mar./Apr. 2000).
	C26	Peng et al., <i>Role of polymers in improving the results of stenting in coronary arteries</i> , Biomaterials 17:685-694 (1996).
	C27	Shigeno, <i>Prevention of Cerebrovascular Spasm By Bosentan, Novel Endothelin Receptor</i> , Chemical Abstract 125:212307 (1996).
	C28	van Beusekom et al., <i>Coronary stent coatings</i> , Coronary Artery Disease 5(7):590-596 (July 1994).
	C29	Wilensky et al., <i>Methods and Devices for Local Drug Delivery in Coronary and Peripheral Arteries</i> , Trends Cardiovasc. Med. 3(5):163-170 (1993).
	C30	Yokoyama et al., <i>Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor</i> , Journal of Controlled Release 50:79-92 (1998).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	